Geron (GERN) Non-Current Debt (2011 - 2026)
Geron (GERN) posted Non-Current Debt of $119.8 million for Q1 2026, little changed sequentially from $119.5 million in Q4 2025, and up 0.93% YoY from $118.7 million in Q1 2025.
Geron (GERN) Non-Current Debt (2011 - 2026) Analysis & Trends
Geron has reported Non-Current Debt for 8 years, with the latest figure at $119.8 million in Q1 2026.
- Quarterly Non-Current Debt rose 0.93% year-over-year to $119.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.8 million (up 0.93% YoY) and the FY2025 annual result came in at $119.5 million, up 0.9% from the prior year.
- Non-Current Debt held at $119.8 million in Q1 2026 per GERN's latest filing, from $119.5 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $119.8 million in Q1 2026 and troughed at $11.2 million in Q1 2024.
- A 5-year average of $64.4 million and a median of $45.3 million in 2022 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt plunged 78.17% in 2024, then surged 958.28% in 2025.
- Over 5 years, Non-Current Debt stood at $30.2 million in 2022, then grew by 16.02% to $35.1 million in 2023, then surged by 238.01% to $118.5 million in 2024, then increased by 0.9% to $119.5 million in 2025, then rose by 0.24% to $119.8 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $119.8 million, $119.5 million, and $119.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 120.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 120.13 Mn |
| Mar 31, 2026 | 119.83 Mn |
| Dec 31, 2025 | 119.55 Mn |
| Sep 30, 2025 | 119.26 Mn |
| Jun 30, 2025 | 118.99 Mn |
| Mar 31, 2025 | 118.73 Mn |
| Dec 31, 2024 | 118.48 Mn |
| Sep 30, 2024 | 12.28 Mn |
| Jun 30, 2024 | 36.52 Mn |
| Mar 31, 2024 | 11.22 Mn |
| Dec 31, 2023 | 35.05 Mn |
| Sep 30, 2023 | 29.84 Mn |
| Jun 30, 2023 | 40.80 Mn |
| Mar 31, 2023 | 51.40 Mn |
| Dec 31, 2022 | 30.21 Mn |
| Sep 30, 2022 | 37.80 Mn |
| Jun 30, 2022 | 45.26 Mn |
| Mar 31, 2022 | 50.18 Mn |
| Dec 31, 2021 | 49.83 Mn |
| Sep 30, 2021 | 34.67 Mn |